학술논문
Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI).
Document Type
Article
Author
Stirrup, Oliver; Krutikov, Maria; Tut, Gokhan; Palmer, Tom; Bone, David; Bruton, Rachel; Fuller, Chris; Azmi, Borscha; Lancaster, Tara; Sylla, Panagiota; Kaur, Nayandeep; Spalkova, Eliska; Bentley, Christopher; Amin, Umayr; Jadir, Azar; Hulme, Samuel; Giddings, Rebecca; Nacer-Laidi, Hadjer; Baynton, Verity; Irwin-Singer, Aidan
Source
Subject
*SARS-CoV-2
*LONG-term care facilities
*COVID-19 vaccines
*
*
Language
ISSN
0022-1899
Abstract
General population studies have shown strong humoral response following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination with subsequent waning of anti-spike antibody levels. Vaccine-induced immune responses are often attenuated in frail and older populations, but published data are scarce. We measured SARS-CoV-2 anti-spike antibody levels in long-term care facility residents and staff following a second vaccination dose with Oxford-AstraZeneca or Pfizer-BioNTech. Vaccination elicited robust antibody responses in older residents, suggesting comparable levels of vaccine-induced immunity to that in the general population. Antibody levels are higher after Pfizer-BioNTech vaccination but fall more rapidly compared to Oxford-AstraZeneca recipients and are enhanced by prior infection in both groups. [ABSTRACT FROM AUTHOR]